PortfoliosLab logoPortfoliosLab logo
ISIN
US2681582019
CUSIP
268158201
IPO Date
Feb 19, 2004

Highlights

Market Cap
$2.12B
Enterprise Value
$2.28B
EPS (TTM)
-$0.32
Total Revenue (TTM)
$330.51M
Gross Profit (TTM)
$274.90M
EBITDA (TTM)
-$25.65M
Year Range
$9.20 - $15.73
ROA (TTM)
-4.59%
ROE (TTM)
-8.13%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

DVAX Performance Chart


Loading charts...

S&P 500 Index

Returns By Period


Dynavax Technologies Corporation

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*

Benchmark (S&P 500 Index)

1D
0.13%
1M
5.68%
YTD
11.16%
6M
11.10%
1Y
27.46%
3Y*
21.12%
5Y*
12.66%
10Y*
13.75%
*Multi-year figures are annualized to reflect compound growth (CAGR)

DVAX Monthly Returns History


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20260.68%0.10%0.78%
20252.19%5.67%-5.95%-9.41%-16.68%1.33%10.69%-7.83%-1.88%3.32%10.82%35.27%20.44%
2024-7.58%-1.93%-2.05%-8.38%5.45%-6.34%-0.36%0.27%-0.71%6.37%8.52%-0.70%-8.66%
20236.95%-9.49%-4.76%6.12%9.80%13.04%8.28%2.64%2.86%-3.79%-3.59%2.04%31.39%
2022-7.82%-5.47%-11.58%-18.54%34.31%6.16%14.22%-20.24%-8.98%9.67%8.38%-14.26%-24.38%
202141.80%38.67%12.34%1.53%-17.84%20.12%-5.18%108.35%-1.28%3.96%-19.13%-12.88%216.18%

Benchmark Metrics

Dynavax Technologies Corporation has an annualized alpha of 36.84%, beta of 0.90, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since February 20, 2004.

  • This stock participated in 195.05% of S&P 500 Index downside but only 155.02% of its upside - more exposed to losses than it benefited from rallies.
  • R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
36.84%
Beta
0.90
0.02
Upside Capture
155.02%
Downside Capture
195.05%

Return for Risk

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Dynavax Technologies Corporation (DVAX) and compare them to S&P 500 Index.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Dividends

Dividend History


Dynavax Technologies Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Dynavax Technologies Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Dynavax Technologies Corporation was 98.47%, occurring on Nov 20, 2008. The portfolio has not yet recovered.


Related event

Drawdown

Fall

Recovery

Underwater

Financial crisis2007–2009
-98.47%Nov 2008
1y 11mo
19y 5moDec 2006 - now
2005 bear market2005
-61.81%Apr 2005
1y 1mo1y 7mo
2y 9moFeb 2004 - Nov 2006
2006 pullback2006
-7.25%Dec 2006
1d10d
11dNov 2006 - Dec 2006

Drawdown Indicators


DVAXBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-56.78%

Max Drawdown (1Y)

Largest decline over 1 year

-9.10%

Max Drawdown (3Y)

Largest decline over 3 years

-18.90%

Max Drawdown (5Y)

Largest decline over 5 years

-25.43%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

0.00%

Average Drawdown

Average peak-to-trough decline

-10.72%

Ulcer Index

Depth and duration of drawdowns from previous peaks

1.97%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Dynavax Technologies Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Dynavax Technologies Corporation is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for DVAX relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, DVAX has a P/S ratio of 6.4. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for DVAX in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, DVAX has a P/B value of 4.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with DVAX

Add Dynavax Technologies Corporation to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with DVAX